Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2016 - 2025)
Alnylam Pharmaceuticals (ALNY) has disclosed Other Non Operating Income for 15 consecutive years, with -$3.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income rose 95.84% year-over-year to -$3.4 million, compared with a TTM value of $5.2 million through Dec 2025, up 102.88%, and an annual FY2025 reading of $5.2 million, up 102.88% over the prior year.
- Other Non Operating Income was -$3.4 million for Q4 2025 at Alnylam Pharmaceuticals, up from -$9.5 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $55.0 million in Q4 2022 and bottomed at -$80.8 million in Q4 2024.
- Average Other Non Operating Income over 5 years is -$22.8 million, with a median of -$20.4 million recorded in 2023.
- Peak annual rise in Other Non Operating Income hit 301.02% in 2022, while the deepest fall reached 369.24% in 2022.
- Year by year, Other Non Operating Income stood at -$27.4 million in 2021, then soared by 301.02% to $55.0 million in 2022, then crashed by 136.99% to -$20.4 million in 2023, then crashed by 297.26% to -$80.8 million in 2024, then skyrocketed by 95.84% to -$3.4 million in 2025.
- Business Quant data shows Other Non Operating Income for ALNY at -$3.4 million in Q4 2025, -$9.5 million in Q3 2025, and $8.9 million in Q2 2025.